Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile (GlobeNewswire) - Oct 23, 2026 - "Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years, without the need for chronic B-cell depletion. MRI disease activity significantly reduced with remibrutinib vs. teriflunomide in two trials, including reductions in T2 lesion activity by 65% and 70%, and Gd+ T1 lesions by 66% across both trials. Over 92% of remibrutinib patients remained free from disease progression as assessed by 6-month CDP, showing clinically meaningful delay of nearly 30% vs. teriflunomide with nominal significance. No liver safety signal observed, including no Hy's Law cases....Novartis plans to seek regulatory approval for remibrutinib in RMS globally."
Filing • P3 data • Retrospective data • Multiple Sclerosis
|